PROCEPT BioRobotics Corporation (PRCT) Income Statement
PRCT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPRCT revenue and net income
Where PRCT's revenue goes
2025Each bar shows an amount and its share of revenue. PRCT kept −31.0% of revenue as net income.
PRCT profit margins
PRCT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +37.2% | +60.1% | +109.0% | — |
| Gross profit | +43.1% | +74.3% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PRCT quarterly EPS vs estimates
PROCEPT BioRobotics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.39).
PRCT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M | $7.7M | $6.2M |
| Cost of revenue | $111.8M | $87.4M | $65.1M | $37.9M | $18.6M | $9.0M | $8.1M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M | −$1.3M | −$1.9M |
| Research & development | $71.3M | $62.3M | $48.4M | $29.0M | $19.0M | $16.3M | $13.1M |
| Sales, general & admin | $228.8M | $171.4M | $121.5M | $88.8M | $51.0M | $30.3M | $28.5M |
| Total operating expenses | $300.1M | $233.7M | $180.2M | $117.8M | $70.0M | $46.5M | $41.7M |
| Operating income | −$103.9M | −$96.6M | −$109.2M | −$80.7M | −$54.2M | −$47.8M | −$43.5M |
| Interest income | $12.2M | $10.9M | $5.6M | $2.5M | $121,000 | $184,000 | $1.1M |
| Interest expense | $3.6M | $4.2M | $4.0M | $5.2M | $5.8M | $5.3M | $724,000 |
| Income before taxes | −$95.4M | −$91.4M | −$105.9M | −$87.2M | −$59.9M | −$53.0M | −$42.0M |
| Income taxes | $190,000 | — | $3.6M | $6.4M | $2.5M | $5.2M | $678,000 |
| Net income | −$95.6M | −$91.4M | −$105.9M | −$87.2M | −$59.9M | −$53.0M | −$42.0M |
| EBITDA | −$85.4M | −$82.0M | −$98.1M | −$79.1M | −$50.7M | −$44.9M | −$39.8M |
| EPS (diluted) | −$1.71 | −$1.76 | −$2.24 | −$1.89 | −$3.78 | −$13.24 | −$4.56 |
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | −16.3% | −30.6% |
| Operating margin | −33.7% | −43.0% | −80.2% | −107.6% | −157.1% | −619.4% | −705.9% |
| Net margin | −31.0% | −40.7% | −77.8% | −116.2% | −173.6% | −687.0% | −680.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.5M | $83.1M | $76.4M | $83.3M | $79.2M | $69.2M | $68.2M | $58.4M | $53.4M | $44.5M | $43.6M | $35.1M |
| Cost of revenue | $32.1M | $29.2M | $30.1M | $30.9M | $29.0M | $25.0M | $24.6M | $21.5M | $21.9M | $19.5M | $22.3M | $16.2M |
| Gross profit | $62.4M | $53.9M | $46.3M | $52.4M | $50.2M | $44.2M | $43.7M | $36.9M | $31.5M | $25.0M | $21.3M | $18.9M |
| Research & development | $20.1M | $21.5M | $19.1M | $16.6M | $16.0M | $16.4M | $15.1M | $16.6M | $17.5M | $13.1M | $14.5M | $11.6M |
| Sales, general & admin | $69.7M | $65.1M | $58.3M | $59.0M | $56.3M | $55.2M | $48.3M | $42.7M | $40.8M | $39.6M | $36.3M | $32.9M |
| Total operating expenses | $89.8M | $86.6M | $77.4M | $75.6M | $72.3M | $71.6M | $63.4M | $59.3M | $58.3M | $52.7M | $50.8M | $44.5M |
| Operating income | −$27.4M | −$32.6M | −$31.0M | −$23.2M | −$22.2M | −$27.4M | −$19.7M | −$22.4M | −$26.8M | −$27.6M | −$29.6M | −$25.6M |
| Interest income | $1.5M | $1.7M | $2.4M | $2.7M | $3.5M | $3.6M | $3.3M | $2.6M | $2.2M | $2.7M | $3.5M | $2.0M |
| Interest expense | $842,000 | $818,000 | $894,000 | $919,000 | $895,000 | $877,000 | $969,000 | $1.1M | $1.0M | $1.0M | $1.1M | $1.0M |
| Income before taxes | −$26.8M | −$31.6M | −$29.7M | −$21.4M | −$19.6M | −$24.7M | −$18.9M | −$21.0M | −$25.6M | −$26.0M | −$27.5M | −$24.6M |
| Income taxes | $94,000 | −$43,000 | $190,000 | — | — | — | — | −$1.3M | — | $1.1M | $1.8M | −$1.1M |
| Net income | −$26.9M | −$31.6M | −$29.8M | −$21.4M | −$19.6M | −$24.7M | −$18.9M | −$21.0M | −$25.6M | −$26.0M | −$27.5M | −$24.6M |
| EBITDA | −$23.9M | −$29.1M | −$27.1M | −$18.9M | −$17.1M | −$22.4M | −$16.4M | −$18.5M | −$23.3M | −$23.7M | −$25.1M | −$22.5M |
| EPS (diluted) | −$0.47 | −$0.56 | −$0.53 | −$0.38 | −$0.35 | −$0.45 | −$0.35 | −$0.40 | −$0.50 | −$0.51 | −$0.54 | −$0.51 |
| Gross margin | 66.0% | 64.9% | 60.6% | 62.9% | 63.3% | 63.9% | 64.0% | 63.2% | 59.0% | 56.2% | 48.8% | 53.8% |
| Operating margin | −29.0% | −39.2% | −40.6% | −27.8% | −28.0% | −39.7% | −28.9% | −38.4% | −50.3% | −62.1% | −67.8% | −73.0% |
| Net margin | −28.4% | −38.1% | −39.1% | −25.7% | −24.7% | −35.8% | −27.6% | −35.9% | −48.0% | −58.3% | −63.1% | −70.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PRCT's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PRCT financial results
In fiscal year 2025 (ended December 31, 2025), PROCEPT BioRobotics reported revenue of $308.1 million, up 37.2% from the year before. It had a net loss of $95.6 million, a net profit margin of −31.0%. Diluted earnings per share came to −$1.71. Over five years revenue grew at an average rate of 109.0% a year.
See the PRCT stock overview for the latest quote and news, or the PRCT chart for price history and technical indicators.
PRCT income statement FAQ
What is PROCEPT BioRobotics's annual revenue?
PROCEPT BioRobotics reported total revenue of $308.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 37.2% from $224.5 million the previous year.
Is PROCEPT BioRobotics profitable?
No. PROCEPT BioRobotics reported a net loss of $95.6 million in fiscal 2025, a net profit margin of −31.0%; its operating margin was −33.7%.
What is PROCEPT BioRobotics's gross margin?
PROCEPT BioRobotics's gross margin was 63.7% in fiscal 2025: for every $100 of revenue, PROCEPT BioRobotics kept $64 after the direct cost of its products and services.
How much does PROCEPT BioRobotics spend on research and development?
PROCEPT BioRobotics spent $71.3 million on research and development in fiscal 2025, 23.1% of revenue.
How fast is PROCEPT BioRobotics growing?
Revenue grew 109.0% a year on average over the last five fiscal years, from $7.7 million to $308.1 million.
What are PROCEPT BioRobotics's earnings per share?
PROCEPT BioRobotics earned $-1.71 per diluted share in fiscal 2025, compared with $-1.76 a year earlier.
When will PROCEPT BioRobotics report its next earnings?
PROCEPT BioRobotics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does PROCEPT BioRobotics's fiscal year end?
PROCEPT BioRobotics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.